Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buti

Showing results (301-310 of 387) with videos related to

Pageof 39
Sort By:
Viruses|November 24, 2022
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health DisordersHeiner Wedemeyer, Vito Di Marco, Montserrat Garcia-Retortillo, et al.
European Journal of Gastroenterology & Hepatology|October 24, 2014
Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbiditiesMaria Buti, Rosa M Morillas, Juan Pérez, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 6, 2026
Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty SurveyTatyana Kushner, Maria Buti, Mohamed El-Kassas, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 19, 2026
Real-World Outcomes of Opti-Hep-D: An Innovative, Multicentre and Multidisciplinary Program Improving Hepatitis D Cascade of CareAdriana Palom, Ariadna Rando-Segura, Laura Calatayud-Samper, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeksScott K Fung, Calvin Q Pan, Grace Lai-Hung Wong, et al.
Journal of Hepatology|October 28, 2023
Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in EuropeLesley A Patmore, Kirsi M A van Eekhout, Maria Buti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 1, 2017
Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN)Anika Wranke, Lourdes M Pinheiro Borzacov, Raymundo Parana, et al.
Gastroenterology|July 1, 2018
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and CirrhosisRafael Esteban, Juan A Pineda, Jose Luis Calleja, et al.
Digestive Diseases and Sciences|January 13, 2017
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular CarcinomaMar Riveiro-Barciela, David Tabernero, José L Calleja, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialMaria Buti, Edward Gane, Wai Kay Seto, et al.
Pageof 39

Showing results (301-310 of 387) with videos related to

Sort By:
Pageof 39
Viruses|November 24, 2022
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health DisordersHeiner Wedemeyer, Vito Di Marco, Montserrat Garcia-Retortillo, et al.
European Journal of Gastroenterology & Hepatology|October 24, 2014
Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbiditiesMaria Buti, Rosa M Morillas, Juan Pérez, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 6, 2026
Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty SurveyTatyana Kushner, Maria Buti, Mohamed El-Kassas, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 19, 2026
Real-World Outcomes of Opti-Hep-D: An Innovative, Multicentre and Multidisciplinary Program Improving Hepatitis D Cascade of CareAdriana Palom, Ariadna Rando-Segura, Laura Calatayud-Samper, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeksScott K Fung, Calvin Q Pan, Grace Lai-Hung Wong, et al.
Journal of Hepatology|October 28, 2023
Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in EuropeLesley A Patmore, Kirsi M A van Eekhout, Maria Buti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 1, 2017
Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN)Anika Wranke, Lourdes M Pinheiro Borzacov, Raymundo Parana, et al.
Gastroenterology|July 1, 2018
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and CirrhosisRafael Esteban, Juan A Pineda, Jose Luis Calleja, et al.
Digestive Diseases and Sciences|January 13, 2017
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular CarcinomaMar Riveiro-Barciela, David Tabernero, José L Calleja, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialMaria Buti, Edward Gane, Wai Kay Seto, et al.
Pageof 39